March 4, 2016. These are the materials from the Senate briefing we hosted on March 4, 2016 with the Patient, Consumer, and Public Health Coalition titled “Innovation for Healthier Americans: The Impact of Proposed Health Bills on Patients & Consumers”.
Read More »On Health Policy
Letter to HELP Committee Re: Innovation Bills
March 5, 2016. This letter from the Patient, Consumer, and Public Health Coalition expresses disappointment that these bills are so biased against the interests of nonprofit member organizations, who represent millions of patients, consumers, scientists, and public health researchers and advocates.
Read More »NCHR Testimony at 2016 FDA Public Meeting on Demographic Subgroup Data
February 29, 2016. The FDA should make it clear that the agency will not approve medical products for all populations if the sponsor has not tested the product for safety and effectiveness on all major demographic subgroups and provided meaningful subgroup analyses.
Read More »Patient, Consumer, and Public Health Coalition Testimony at 2016 FDA Public Meeting on Demographic Subgroup Data
February 29, 2016. The FDA should make it clear that the agency will not approve medical products for all populations if meaningful subgroup analysis for safety and effectiveness were not conducted for major demographic groups.
Read More »NCHR Testimony at FDA on Allergy Products
January 21, 2016. Allergies can be a life-and-death situation. Treatment options for food allergies could save lives, significantly improve quality of life for many families, and reduce the number of severe reactions from occurring. We must require that clinical trials study all of the necessary variables to help families make informed treatment choices.
Read More »